bluebird bio (LSE:0HOH) - 주가, 뉴스 및 분석

0HOH 주식 개요

는 미국에서 중증 유전 질환 치료를 위한 유전자 치료제를 연구, 개발 및 상용화하는 생명공학 회사입니다. 자세한 내용

0HOH 기본 분석
눈송이 점수
가치 평가	5/6
미래 성장	2/6
과거 실적	0/6
재무 상태	0/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 95.8% 에서 거래

수익은 연간 41.53% 증가할 것으로 예상됩니다.

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

지난 1년 동안 주주가 크게 희석되었습니다.

cash runway 경력이 1년 미만입니다.

마이너스 주주 지분

최근 3개월간 주가 변동폭 심해

+ 2 더 많은 위험

bluebird bio, Inc. 경쟁사

Arecor Therapeutics

AIM:AREC

UK£28.9m

Avacta Group

AIM:AVCT

UK£168.3m

Tissue Regenix Group

AIM:TRX

UK£41.0m

BSF Enterprise

LSE:BSFA

UK£3.0m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 bluebird bio
과거 주가
현재 주가	US$0.36
52주 최고치	US$5.53
52주 최저치	US$0.29
베타	0.80
11개월 변경	-27.32%
3개월 변경 사항	-40.60%
1년 변경 사항	-90.67%
33년 변화	-96.48%
5년 변화	-99.52%
IPO 이후 변화	-99.82%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	0HOH	GB Biotechs	GB 마켓
7D	20.4%	1.5%	1.7%
1Y	-90.7%	-16.3%	8.4%

수익률 대 산업: 0HOH 지난 1년 동안 -16.3 %를 반환한 UK Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: 0HOH 지난 1년 동안 8.4 %를 반환한 UK 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is 0HOH's price volatile compared to industry and market?
0HOH volatility
0HOH Average Weekly Movement	12.9%
Biotechs Industry Average Movement	9.0%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

안정적인 주가: 0HOH 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: 0HOH 의 주간 변동성( 13% )은 지난 1년 동안 안정적이었지만 여전히 UK 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
1992	282	Andrew Obenshain	www.bluebirdbio.com

는 미국에서 중증 유전 질환 치료를 위한 유전자 치료제를 연구, 개발 및 상용화하는 생명공학 회사입니다. 이 회사의 중증 유전 질환 치료 제품 후보로는 수혈 의존성 지중해빈혈 치료제 진테글로(ZYNTEGLO, 베티베글로겐 오토템셀), 겸상 적혈구 질환(SCD) 치료제 로보티베글로겐 오토템셀, 뇌부신백질이영양증 치료제 스카이소나(스카이소나 엘리발도진 오토템셀) 등이 있습니다. 임상 개발 프로그램에는 SCD 환자 치료에서 로보셀의 안전성과 효능을 평가하기 위한 HGB-205, HGB-206 및 HGB-210과 지중해빈혈 환자 치료에서 베티셀의 안전성과 효능을 평가하기 위한 HGB-204, HGB-205, HGB-207 및 HGB-212가 있습니다.

bluebird bio, Inc. 기본 사항 요약

bluebird bio 의 수익과 매출은 시가총액과 어떻게 비교하나요?
0HOH 기본 통계
시가총액	US$71.94m
수익(TTM)	-US$292.82m
수익(TTM)	US$53.12m

1.4x

P/S 비율

-0.2x

P/E 비율

0HOH 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
0HOH 손익 계산서(TTM)
수익	US$53.12m
수익 비용	US$78.78m
총 이익	-US$25.66m
기타 비용	US$267.16m
수익	-US$292.82m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.51
총 마진	-48.31%
순이익 마진	-551.25%
부채/자본 비율	-1,394.4%

0HOH 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

0HOH 주식 개요

보상

위험 분석

bluebird bio, Inc. 경쟁사

AIM:AREC

UK£28.9m

AIM:AVCT

UK£168.3m

AIM:TRX

UK£41.0m

LSE:BSFA

UK£3.0m

가격 내역 및 성능

최근 뉴스 및 업데이트

Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.66 loss in 3Q 2023)

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

Recent updates

Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.66 loss in 3Q 2023)

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Now 41% undervalued after recent price drop

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Revenue and earnings growth

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.94 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Now 20% undervalued after recent price drop

New minor risk - Insider selling

President recently sold US$60k worth of stock

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$1.36 loss in 2Q 2022)

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

First quarter 2023 earnings released: EPS: US$0.21 (vs US$1.66 loss in 1Q 2022)

Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021)

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.94 loss per share (vs US$2.23 loss in 3Q 2021)

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

Treasurer recently sold US$78k worth of stock

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

President recently sold US$96k worth of stock

Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021)

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Less than half of directors are independent

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022

Bluebird Bio, Inc. Announces Executive Changes

bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer

CEO & Director recently sold US$74k worth of stock

bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. to Launch Both beti-cel and eli-cel for Patients in the U.S. in Mid-2022